ClinicalTrials.gg
TerminatedNCT07314060Updated Aug 3, 2026

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

A Phase 2 interventional study of TQH2929 Injections and TQH2929 Placebo in Generalized Pustular Psoriasis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 31 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
149th of 182
36 · median 171
Started
2026
with 17 others
Phase 2
42 of 206
11 open now
Registered
182nd of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 149th largest by enrollment of the 182 interventional ones that give a count, is one of 18 that started in 2026, is one of 42 in phase 2, and was the 182nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.

03

Conditions studied

  • Generalized Pustular Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 or ≤75 years old at screening, regardless of gender;
  • Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as (generalized pustular psoriasis(GPP);
  • Compliant with GPP acute onset;
  • Able to read and understand, and willing to sign the form;
  • Willing and compliant with study visits and related procedures;
  • Female subjects of childbearing age should agree that measures must be used during the study and for 6 months after the end of the study;

Exclusion criteria

Exclusion Criteria:

  • Pustules are limited to psoriasis vulgaris on psoriasis plaques;
  • Concomitant skin disease or medical disease that may interfere with the investigator's evaluation of the subject's treatment response;
  • Presence of severe, progressive, or uncontrolled disease, or signs and symptoms that are not suitable for participation in the investigator, in the judgment of the investigator:
  • Serum virological abnormalities during the screening period;
  • Chest radiology examination shows that the subject has active tuberculosis or a history of contact with open tuberculosis subjects in the past 6 months or a positive Interferon-Gamma Release Assays(IGRA) test;
  • History of serious infection leading to hospitalization within 2 months prior to baseline;
  • Active infection requiring systemic antibiotics, systemic antifungals, or systemic antiviral therapy within 2 weeks prior to baseline, according to the investigator's assessment;
  • History of opportunistic infection within 6 months prior to baseline;
  • Received live (attenuated) vaccine treatment within 12 weeks prior to baseline;
  • Any major surgery within 4 weeks prior to baseline or planned major surgery during the study;
  • Received blood transfusion within 4 weeks prior to baseline;
  • Participated in clinical trials of other drugs or medical devices within 4 weeks before baseline;
  • Any known or suspected congenital or acquired immunodeficiency state or condition that may compromise the subject's immune status;
  • Subjects with any type of active or a history of malignancy;
  • Alcohol, drug and known drug dependence;
  • Pregnant or lactating women;
  • Subjects cannot tolerate intravenous infusion administration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    TQH2929 Injections

    Intravenous infusion, single dose

    Drug: TQH2929 Injections

  • Placebo comparator
    TQH2929 Placebo

    Intravenous infusion, single dose

    Drug: TQH2929 Placebo

Interventions

  • TQH2929 is a humanized monoclonal antibody that interfering with the signal cascade.

  • DrugTQH2929 Placebo

    Placebo contains no active substance.

06

What researchers measure

Primary outcomes

  1. Percentage of patients with a score of 0 for the pustule subterm

    Percentage of patients with a Physician's Global Assessment of Generalized Pustular Psoriasis (GPPGA) pustular subitem of 0 (no visible pustules) at week 1 among all enrolled patients.

    Time frame: 1 week

Secondary outcomes

  1. Percentage of patients with a Generalized Pustular Psoriasis Physician Global Assessment(GPPGA) total score of 0 or 1

    Percentage of patients with a total Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 (clear) or 1 (almost clear) at weeks 1 and 4.

    Time frame: 1 week and 4 weeks

  2. Percentage change from baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) total score

    Percentage change from baseline in the total score of generalized pustular psoriasis area and severity index (GPPASI) at week 1 and week 4.

    Time frame: 1 week and 4 weeks

  3. Change from baseline in Generalized Pustular Psoriasis Area and Severity Index(GPPASI) total score

    Change from baseline in Generalized Pustular Psoriasis Area and Severity Index(GPPAS) total score at week 1 and week 4. If lower than the baseline score, indicate a certain degree of disease relief; conversely, if higher, it indicates an aggravation of the disease symptoms.

    Time frame: 1 week and 4 weeks

  4. Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 50

    Percentage of patients who achieved Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 50 at week 1 and week 4.

    Time frame: 1 week and 4 weeks

  5. Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 75

    Percentage of patients who achieved Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 75 at week 1 and week 4

    Time frame: 1 week and 4 weeks

  6. Percentage of patients with pustule subterm achieving a score of 0

    Percentage of patients with Generalized Pustular Psoriasis Physician Global Assessment(GPPGA) pustule subterm achieving a score of 0 (no visible pustules) at week 4.

    Time frame: 4 weeks

  7. Change from baseline in Psoriasis Symptom Scale (PSS) score

    Change from baseline in Psoriasis Symptom Scale (PSS) score at week 4

    Time frame: 4 weeks

  8. Change from baseline in disease life quality index (DLQI)

    Change from baseline in skin disease life quality index (DLQI) at week 4. If lower than the baseline score, indicate a certain degree of disease relief; conversely, if higher, it indicates an aggravation of the disease symptoms.

    Time frame: 4 weeks

  9. Adverse Drug Event (AE)

    Any untoward medical occurrence of a subject following drug treatment or exposure to an experimental factor, whether or not causally related to treatment or exposure.

    Time frame: 113 days or 169 days

  10. Serious Adverse Event (SAE)

    An event that occurs in the course of a clinical trial that results in the death of a subject or patient, serious deterioration in health, hospitalization or prolongation of hospitalization, permanent disability or loss of function, or serious consequences such as birth defects or birth defects.

    Time frame: 113 days or 169 days

  11. Treatment-Emergent Adverse Events (TEAES)

    Adverse events that occur during treatment, including from the start of treatment to a certain period of time after the end of treatment, may be directly or indirectly related to treatment.

    Time frame: 113 days or 169 days

  12. Abnormal clinical laboratory examination indicators

    Any laboratory abnormalities that occur during the test.

    Time frame: 113 days or 169 days

  13. Time of maximum concentration (Tmax)

    It refers to the time it takes for the human blood concentration curve to reach the highest concentration (peak concentration) after a single dose, measured in hours or minutes.

    Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose

  14. Maximum Concentration (Cmax)

    The highest blood concentration reached after the drug is absorbed in the body.

    Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose

  15. Area Under the Curve (AUC)

    It refers to the area covered by the concentration of a drug in the blood under the curve of changes over time.

    Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose

  16. Apparent Volume of Distribution(Vd/F)

    When the drug reaches dynamic equilibrium in the body, the ratio of the amount of drug in the body to the blood concentration is called the apparent volume of distribution.

    Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose

  17. Apparent Clearance (CL/F)

    The sum of drug clearance rates of liver and kidney, etc.

    Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose

  18. Plasma half-life time (t1/2)

    The time it takes for the concentration of the drug in the plasma to drop by half.

    Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose

  19. Anti-drug antibody (ADA)

    Incidence of anti-drug antibodies (ADA) in subjects.

    Time frame: Through study completion, an average of half a year

07

Study locations

31 sites
  • Peking University First Hospita
    Beijing, Beijing Municipality 100034, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350000, China
  • Southern Medical University Dermatology Hospital
    Guangzhou, Guangdong 510091, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou 550004, China
  • The Second Hospital Of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • The Second Affiliated Hospital of Henan University of science and technology
    Luoyang, Henan 471000, China
  • Zhengzhou Central Hospital
    Zhengzhou, Henan 450000, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • The fifth Affiliated hospital of zhengzhou university
    Zhengzhou, Henan 450052, China
  • Shiyan Renmin Hospital
    Shiyan, Hubei 442000, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • The First Hospital of Hunan University of Chinese Medicine
    Changsha, Hunan 410007, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • The General Hospital Of Hunan University Of Medicine
    Huaihua, Hunan 41800, China
  • The first hospital of jilin university
    Changchun, Jilin 130012, China
  • The first hospital of china medical university
    Shenyang, Liaoning 110001, China
  • Shandong First Medical University Affiliated Dermatology Hospital
    Jinan, Shandong 250022, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality 200443, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi 710061, China
  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610000, China
  • Sichuan Provincial People' s Hospital
    Chengdu, Sichuan 610000, China
  • The Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan 646000, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin Municipality 300120, China
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Ürümqi, Xinjiang 830001, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830013, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • Jiaxing First Hospital
    Jiaxing, Zhejiang 314001, China
  • The first affiliated hospital of ningbo university
    Ningbo, Zhejiang 315020, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in Jul 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 2, 2026
StartActual
Mar 19, 2026
Primary completionActual
Jul 30, 2026
CompletionActual
Jul 30, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07314060
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Mar 19, 2026
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026
Last update
Aug 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQH2929

Start the discussion